Patents Issued in August 6, 2015
  • DONEPEZIL COMPOSITIONS AND METHODS OF TREATING ALZHEIMERS DISEASE
    Publication number: 20150216849
    Abstract: Oral dosage forms comprising donepezil or a pharmaceutically acceptable salt thereof (e.g., donepezil hydrochloride) alone or in combination with a second active ingredient (e.g., memantine hydrochloride or a pharmaceutically acceptable salt thereof) for the treatment of Alzheimer's disease are provided. The oral dosage forms comprise donepezil granules that may be sprinkled on food and can significantly improve compliance in patients with swallowing difficulty.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Mahendra G. Dedhiya, Kavita Vermani, Ashok Katdare
  • COMBINATION OF RASAGILINE AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
    Publication number: 20150216850
    Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease, comprising administering to the patient rasagiline as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising rasagiline and pridopidine for treating a patient afflicted with a neurodegenerative disorder. This invention also provides rasagiline for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder. This invention further provides use of rasagiline and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder.
    Type: Application
    Filed: September 27, 2013
    Publication date: August 6, 2015
    Inventors: Michael HAYDEN, Cheryl FITZER-ATTAS
  • Polymorphs of Cocrystals of p-Coumaric Acid:Nicotinamide
    Publication number: 20150216851
    Abstract: Polymorphs, Forms II and III, of cocrystals of p-coumaric acid and nicotinamide in a 1:1 molar ratio. Pharmaceutical compositions containing Forms II or III, processes for making such forms, and methods of treatment with such Forms.
    Type: Application
    Filed: January 28, 2015
    Publication date: August 6, 2015
    Inventors: Melanie Janelle Bevill, Nate Schultheiss
  • PHARMACEUTICAL FORMULATIONS CONTAINING IPIDACRINE AND THEIR USE FOR THE TREATMENT OF DISORDERS OF POTENCY AND DISORDERS OF OTHER FORMS OF SEXUAL ACTIVITY
    Publication number: 20150216852
    Abstract: The invention is based on the use of ipidacrine to treat potency disorders and can be used in clinics for treating potency disorders related to the reduced production of reproductive gland hormones, disorders caused by chronic, including physical, stress, and also associated with spontaneously reduced sexual function, including anorgasmia or delayed ejaculation, and other sexual activity disorders not limiting the scope of the invention.
    Type: Application
    Filed: August 15, 2013
    Publication date: August 6, 2015
    Inventors: Vladimir Nikolaevich Bykov, Aleksandr Sergeevich Nikiforov, Galina Aleksandrovna Kim
  • METHOD OF SCREENING ANTI-PLASMODIAL ACTIVITY OF ACRIFLAVIN AND ACRIFLAVIN AS AN ANTI-MALARIAL AGENT
    Publication number: 20150216853
    Abstract: The present invention provides a method of screening anti-plasmodial activity of Acriflavin, comprising assessing growth inhibition of plasmodium in vitro in chloroquine susceptible and cloroquine resistant plasmodium by Acriflavin; or measuring in-vivo plasmodium killing ability of Acriflavin; assessing localization of Acriflavin at different stages; and analyzing effect of Acriflavin on gyrase activity wherein said method utilizes Acriflavin in nano-molar range. The present invention relates to potency of Acriflavin (Acriflavin) as an anti-malarial agent both in vitro parasite culture as well as in vivo. More specifically, the invention relates to a method o determining anti-plasmodial activity, Acriflavin as potent anti-malarial agent and also relates to composition(s) comprising Acriflavin.
    Type: Application
    Filed: July 4, 2013
    Publication date: August 6, 2015
    Inventor: Suman Kumar Dhar
  • Use Of Flap Inhibitors To Reduce Neuroinflammation Mediated Injury In The Central Nervous System
    Publication number: 20150216854
    Abstract: The present invention provides methods of attenuating or preventing brain injury mediated damage in the central nervous system by attenuating or preventing leukotriene-mediated events following a brain injury or long-term neuroinflammation after brain injury, in Alzheimer's disease, multiple sclerosis, stroke, and post-traumatic stress disorder. The methods comprise administering at least one 5-lipoxygenase activating protein (FLAP) inhibitor either before or after the brain injury. The method finds use in the treatment of traumatic brain injury (TBI), stroke, multiple sclerosis, Alzheimer's disease, post-traumatic stress disorder and other brain injuries associated with production of leukotrienes in the central nervous system. Preferably the FLAP inhibitor is administered intranasally and preferably for certain high risk individuals prophylactically prior to any potential brain injury event.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Kim A. Heidenreich, Robert C. Murphy
  • Modulators of Hepatic Lipoprotein Metabolism
    Publication number: 20150216855
    Abstract: The present invention relates to compounds that are useful for modulating hepatic cholesterol metabolism in an animal. The invention includes methods of making and using the compounds of the invention. The invention further provides methods of treating, preventing and/or alleviating a cholesterol related disorder, a cardiovascular disease and/or liver disease in an animal, such as a human, comprising administering compounds of the invention, or pharmaceutically acceptable salts or solvates thereof, to the animal.
    Type: Application
    Filed: August 19, 2013
    Publication date: August 6, 2015
    Inventors: Marek Maria Nagiec, Jose R. Perez, Michelle Palmer, Adam Skepner, Eamon Comer
  • STABLE PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN, AND METHOD FOR PREPARING THE SAME
    Publication number: 20150216856
    Abstract: The present invention relates to a solifenacin preparation containing solifenacin or a pharmaceutically acceptable salt thereof, an antioxidant, and a binder, which is manufactured via direct compression. Compared to the preparations manufactured via conventional wet granulation process, the preparation of the present invention can be manufactured by a simplified process such as direct compression, and has improved content uniformity, mixing degree, etc., even when the preparation is manufactured by high speed tableting.
    Type: Application
    Filed: January 29, 2015
    Publication date: August 6, 2015
    Inventors: Young Hee Suh, Young Dae Cho, Chun Seon Lyu, Mi Young Yoon, Ha Yong Choi, Sung Kyun Han
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20150216857
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 30, 2015
    Publication date: August 6, 2015
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
    Publication number: 20150216858
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: February 3, 2015
    Publication date: August 6, 2015
    Inventors: Michelle Hummel, Donald J. Kyle, Garth Whiteside
  • SUBLINGUAL APOMORPHINE
    Publication number: 20150216859
    Abstract: The invention features sublingual formulations of apomorphine and apomorphine prodrugs, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders therewith.
    Type: Application
    Filed: April 10, 2015
    Publication date: August 6, 2015
    Inventors: Anthony John GIOVINAZZO, David Bruce HEDDEN, Marc L. DE SOMER, Nathan John BRYSON
  • THERAPEUTIC AGENT FOR SYSTEMIC BONE DISEASE AND USE THEREOF
    Publication number: 20150216860
    Abstract: The object is to provide a novel therapeutic strategy achieving high therapeutic effect on a skeletal dysplasia caused by excessive activation of FGFR3, particularly achondroplasia and hypochondroplasia. Provided is a therapeutic agent for a skeletal dysplasia, including meclizine or its pharmaceutically acceptable salt as an active ingredient.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 6, 2015
    Applicant: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Kinji Ohno, Naoki Ishiguro, Hiroshi Kito, Masaki Matsushita
  • CYCLOPROPYL AMIDE DERIVATIVES
    Publication number: 20150216861
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Application
    Filed: April 13, 2015
    Publication date: August 6, 2015
    Inventors: James Arnold, Andrew Todd Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES
    Publication number: 20150216862
    Abstract: The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapes, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 6, 2015
    Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
  • SUBSTITUTED BICYCLIC ALKOXY PYRAZOLE ANALOGS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
    Publication number: 20150216863
    Abstract: In one aspect, the invention relates to substituted bicyclic alkoxy pyrazole analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: April 3, 2015
    Publication date: August 6, 2015
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Gregor James Macdonald, Han Min Tong, Manuel Jesús Alcázar-Vaca, José Ignacio Andrés-Gil, Miguel Angel Pena-Piñón
  • POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
    Publication number: 20150216864
    Abstract: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Inventors: Rajinder Singh, Thilo J. Heckrodt, Sacha Holland
  • METHODS OF TREATING A BRUTON'S TYROSINE KINASE DISEASE OR DISORDER
    Publication number: 20150216865
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: September 3, 2013
    Publication date: August 6, 2015
    Inventors: William Frederick Westlin, III, Erica Evans Raab, Zebulun David Horowitz, Claudia Eve Kasserra, Lisa Beebe, Maria Palmisano, Gondi Nagendra Kumar, Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, Deqiang Niu, Lixin Qiao
  • SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS
    Publication number: 20150216866
    Abstract: The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.
    Type: Application
    Filed: April 15, 2015
    Publication date: August 6, 2015
    Inventors: Anima BARUAH, Dibyendu DE, Ish Kumar KHANNA, Sivaram PILLARISETTI, Santanu MAITRA, Christopher W. ALEXANDER, Jennepalli SREENU, Indu DAGER, Shanavas ALIKUNJU
  • COMPOUNDS FOR USE IN GASTRIC COMPLICATION
    Publication number: 20150216867
    Abstract: The present invention relates to the use of low molecular weight (lmw) compounds, especially lmw compounds with GPR4-affinity, in the treatment of diseases and disorders which includes gastroesophageal reflux disease (GERD), and/or non-erosive reflux disease (NERD) and the like.
    Type: Application
    Filed: September 23, 2013
    Publication date: August 6, 2015
    Applicant: NOVARTIS AG
    Inventors: Andreas Christ, Loetcher Pius, Stephen John Oliver
  • Method of Adjuvant Cancer Treatment
    Publication number: 20150216868
    Abstract: The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
    Type: Application
    Filed: August 30, 2013
    Publication date: August 6, 2015
    Applicant: GlaxoSmithKline LLC
    Inventors: Sylvie Laquerre, Peter F. Lebowitz
  • Drug Combinations and Uses in Treating a Coughing Condition
    Publication number: 20150216869
    Abstract: The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.
    Type: Application
    Filed: April 15, 2015
    Publication date: August 6, 2015
    Applicant: Biocopea Limited
    Inventors: John Brew, Robin Mark Bannister
  • Combination of PI3K Inhibitor and C-Met Inhibitor
    Publication number: 20150216870
    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 6, 2015
    Applicant: Novartis AG
    Inventors: Giordano Caponigro, Xizhong Huang, Joseph Lehar, Hui-Qin Wang
  • Use of a Humic Acid Preparation for Treating Warm-Blooded Animals
    Publication number: 20150216871
    Abstract: The invention relates to the use of a humic acid preparation RB4 or lignocellulose carbon isolate for treating diseases in warm-blooded animals cause by glyphosate herbicide, whereby the glyphosate herbicide is bound to the humic acid preparation and reduced the growth-inhibiting effect of glyphosate herbicide on physiological germs. The invention also related to the use of humic acid preparation RB4 or lignocellulose carbon isolate for external skin application so that it leads to the improvement or maintenance of skin health.
    Type: Application
    Filed: September 11, 2013
    Publication date: August 6, 2015
    Inventors: Manfred Kühnert, Monika Krüger, Svent Haufe, Awad Sheata
  • METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES
    Publication number: 20150216872
    Abstract: A method of treating polycystic kidney disease in a subject comprises administering to the subject an effective amount of a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 4, 2014
    Publication date: August 6, 2015
    Inventors: Thomas A. Natoli, Oxana Ibraghimov-Beskrovnaya, John P. Leonard, Nelson S. Yew, Seng H. Cheng
  • METHODS OF TREATING PATIENTS CO-INFECTED WITH HIV AND TUBERCULOSIS
    Publication number: 20150216873
    Abstract: The disclosure describes methods for treatment of patients co-infected with HIV and tuberculosis, wherein the patient receives effective amounts of elvitegravir, an antimycobacterial agent and a CYP inhibitor.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Rebecca Restituto Begley, Joseph Marcello Custodio, Brian P. Kearney
  • ANTIBIOTIC COMPOSITIONS AND METHODS
    Publication number: 20150216874
    Abstract: Disclosed is a novel family of antibiotic that provides bacteria specific targeting, activation and the ability to prevent bacteria mutations that result in bacteria resistance. The compositions and methods of the invention provide for an antibiotic that is effective against Methicillin-resistant Staphylococcus aureus (MRSA).
    Type: Application
    Filed: January 7, 2015
    Publication date: August 6, 2015
    Applicant: Truox, Inc.
    Inventor: Roy Martin
  • MODULATING THE PRODUCTION OF NEURONS AND/OR OLIGODENDROCYTES FROM WHITE MATTER PROGENITOR CELLS
    Publication number: 20150216875
    Abstract: The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.
    Type: Application
    Filed: December 29, 2014
    Publication date: August 6, 2015
    Inventors: Steven A. GOLDMAN, Fraser SIM
  • METHOD FOR TREATING INFLAMMATORY CONDITIONS
    Publication number: 20150216876
    Abstract: A method for treating an autoimmune disease in a subject includes administering to the subject a therapeutically effective amount of an agent comprising an imidazole, an estrogen receptor agonist, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 13, 2015
    Publication date: August 6, 2015
    Inventor: Rekha Bansal
  • COMPOSITIONS AND TREATMENT FOR EYE DISEASES AND DISORDERS
    Publication number: 20150216877
    Abstract: The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.
    Type: Application
    Filed: July 26, 2013
    Publication date: August 6, 2015
    Inventors: Wei-Wei Chang, Kenneth Sawyer
  • 17 Alpha, 21-Dihydroxypregnene Esters as Antiandrogenic Agents
    Publication number: 20150216878
    Abstract: 17?,21 -Dihydroxypregna-4,9(11)-diene-3,20-dione and 17?,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity and processes for the preparation thereof.
    Type: Application
    Filed: September 2, 2014
    Publication date: August 6, 2015
    Inventors: Mauro AJANI, Luigi MORO
  • Methods and Compositions for the Treatment of Fluid Accumulation in and/or Under the Retina
    Publication number: 20150216879
    Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.
    Type: Application
    Filed: January 2, 2015
    Publication date: August 6, 2015
    Inventors: Francine Behar-Cohen, Nicolette Farman, Frederic Jaisser
  • INDUCING LACTATION IN NURSING FEMALES
    Publication number: 20150216880
    Abstract: A topical cream applied to a nipple of a lactating female induces lactation. The cream comprises a base cream having from about 0.5% to about 10%, by volume, of a steroid, based upon the total volume of the cream. The preferred steroid is stanozolol. Preferably, the cream comprises at least about 1% to about 10%, by volume, of stanozolol, based on the total volume of the cream.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventor: Edward M. Lichten
  • Method for Treating Secondary Hyperparathyroidism in CKD
    Publication number: 20150216881
    Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 6, 2015
    Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
  • High-Purity Phospholipids
    Publication number: 20150216882
    Abstract: Novel synthetic routes, which are highly applicable for industrial preparation of therapeutically beneficial oxidized phospholipids, are disclosed. Particularly, novel methods for efficiently preparing compounds having a glycerolic backbone and one or more oxidized moieties attached to the glycerolic backbone, which are devoid of column chromatography are disclosed. Further disclosed are novel methods of introducing phosphorus-containing moieties such as phosphate moieties to compounds having glycerolic backbone and intermediates formed thereby. Further disclosed is substantially pure 1-hexadecyl-2-(4?-carboxy)butyl-sn-glycero-3-phosphocholine (CI-201).
    Type: Application
    Filed: February 25, 2015
    Publication date: August 6, 2015
    Inventors: Gideon Halperin, Eti Kovalevski-Ishai
  • DIETARY SUPPLEMENT CONTAINING PHOSPHOLIPID-DHA DERIVED FROM EGGS
    Publication number: 20150216883
    Abstract: Described herein are manufactured dietary supplements that contain a phospholipid extract and the extract contains two forms of phospholipid-docosahexanoic acid. One form of phospholipid-docosahexanoic acid is phosphatidylcholine-docosahexanoic acid, and another form of phospholipid-docosahexanoic acid is phosphatidylethanolamine-docosahexanoic acid.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Inventor: Rhett Sean Daniels
  • Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Low Back Pain
    Publication number: 20150216884
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: April 14, 2015
    Publication date: August 6, 2015
    Inventor: Herriot Tabuteau
  • BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS
    Publication number: 20150216885
    Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Inventors: Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
  • METHODS FOR TREATING CANCERS USING ORAL FORMULATIONS OF CYTIDINE ANALOGS
    Publication number: 20150216886
    Abstract: Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Inventors: Kyle J. MACBETH, Aaron N. NGUYEN, Jorge DIMARTINO
  • Compositions for Oral Administration to Animals, Production Methods thereof and Uses of Same
    Publication number: 20150216887
    Abstract: The invention relates to a method for the production of a time-stable, solid appetising composition and to the use thereof, said composition comprising at least one active substance which is introduced in the final production step, by adding same to the already formed mixture of other components at ambient temperature, without the use of water or heat. The composition is intended for use as a drug, a nutraceutical or a food supplement for oral administration to mammals, except humans, in particular for pets such as dogs, cats or horses. The stable solid composition is obtained by compressing the mixture using a press for compressing formulations having a high fat content.
    Type: Application
    Filed: August 29, 2013
    Publication date: August 6, 2015
    Inventors: Guy Derrieu, Giancarlo Mazzola
  • ANTIPARASITIC POLYANHYDRIDE NANOPARTICLES
    Publication number: 20150216888
    Abstract: Filarial parasites Brugia, Wuchereria, Loa Loa and Onchocerca cause over 20 million infections worldwide and pose a significant social and economic burden in endemic areas. The invention provides compositions and methods to treat parasitic infections in animals and plants, and to kill and inhibit the replication of parasites in infected hosts. The methods can include administering to a host in need of treatment an effective antiparasitic amount of a composition comprising biodegradable polyanhydride microparticles or nanoparticles that encapsulate antiparasitic agents, optionally in combination with antibacterial agents. Through co-encapsulation of antiparasitic and antibacterial agents into the particles, the invention provides the ability to effectively kill parasitic helminthes, worms, and flukes, with up to a 40-fold reduction in the amount of drug used.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Applicant: Iowa State University Research Foundation, Inc.
    Inventors: Bryan Howard Bellaire, Balaji Narasimhan
  • A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION
    Publication number: 20150216889
    Abstract: The present disclosure provides an A3 adenosine receptor (A3AR) ligand for the treatment of sexual dysfunction. In some embodiments the A3AR ligand is selected from an A3AR agonist and A3AR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction, the method comprises administering to a subject having the sexual dysfunction an amount of an A3 adenosine receptor (A3AR) ligand. In some embodiments, the A3AR ligand is an A3AR agonist and more specifically, IB-MECA.
    Type: Application
    Filed: August 8, 2013
    Publication date: August 6, 2015
    Applicant: CAN-FITE BIOPHARMA LTD.
    Inventor: Pnina Fishman
  • METHOD OF TREATING LEUKEMIA
    Publication number: 20150216890
    Abstract: The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: September 6, 2013
    Publication date: August 6, 2015
    Applicant: Epizyme, Inc.
    Inventors: Edward J. Olhava, Richard Chesworth, Kevin W. Kuntz, Victoria M. Richon, Roy M. Pollock, Scott Richard Daigle
  • NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS
    Publication number: 20150216891
    Abstract: The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm), UNIVERSITE DE LA MEDITARRANEE AIX-MARSEILLE II
    Inventors: Palma ROCCHI, Virginie BAYLOT, Julie ACUNZO, Claudia ANDRIEU, Maria KATSOGIANNOU
  • CELL-SPECIFIC DELIVERY OF MIRNA MODULATORS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
    Publication number: 20150216892
    Abstract: Compositions comprising microRNAs (miRNAs) and targeting agents are disclosed, as well as methods for delivering a therapeutic composition comprising the same, and the use of these compositions to treat obesity or cardiometabolic disorders. In some aspects, the compositions comprise a miRNA agent and a targeting agent. In some embodiments, the targeting agent may be an aptamer, an exosome, or both an aptamer and an exosome.
    Type: Application
    Filed: August 5, 2013
    Publication date: August 6, 2015
    Inventor: Marc Thibonnier
  • METHODS AND COMPOSITIONS FOR INHIBITING A MULTI-CANCER MESENCHYMAL TRANSITION MECHANISM
    Publication number: 20150216893
    Abstract: The present invention relates to the discovery that the modulation of particular microRNAs can be employed to inhibit a mesenchymal transition that, in certain instances, correlates with resistance to therapy and recurrence as the corresponding cells acquire properties of stem cells as they start undergoing this transition, as well as with invasiveness, e.g., invasion of certain cells of primary tumors into adjacent connective tissue during the initial phase of metastasis. Accordingly, the identification inhibitors of this mechanism, such as inhibitors of certain microRNAs, disclosed herein, can be used for inhibiting the mesenchymal transition to reduce the invasive nature of certain cells of primary cancerous tumors and, in certain instances, to prevent the recurrence of cancer by inhibiting the induction of stem cell-like features in certain cancer cells.
    Type: Application
    Filed: August 13, 2014
    Publication date: August 6, 2015
    Inventor: Dimitris Anastassiou
  • Chitosan Materials from Carbonic Acid Solution
    Publication number: 20150216894
    Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Inventors: Simon McCarthy, Barbara McGrath, Sam Kuhn, Jess Kimball, Michael Stolten, Amanda Bennett
  • CYCLODEXTRIN FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
    Publication number: 20150216895
    Abstract: The invention provides for methods of treating lysosomal storage disorders and/or reduction of non-cholesterol lipids, using cyclodextrin compounds, including in combination with other therapeutics, including vitamin E.
    Type: Application
    Filed: August 3, 2013
    Publication date: August 6, 2015
    Inventors: John McKew, Wei Zheng, Miao Xu, Manju Swaroop, Juan J. Marugan
  • MICELLE SEQUESTERING POLYMERS
    Publication number: 20150216896
    Abstract: A polymer composition for sequestering lipid-bile acid micelles in the gastrointestinal (GI) tract is provided. The polymer composition comprises a copolymer of a pH-sensitive monomer and one or more of positively-charged monomers. The polymer composition is able to bind micelles under various physiological conditions in the GI tract and possesses the ability to flocculate the bound micelle upon exposure to a particular pH. The flocculation of the polymer:micelle complex prevents absorption of the micelle thereby causing the polymer:micelle complex to be eliminated with the fecal matter. Thus, the polymer composition described herein may be effective in reducing cholesterol, bile acid, and/or triglyceride levels and promote weight loss.
    Type: Application
    Filed: January 29, 2015
    Publication date: August 6, 2015
    Inventors: Cory Berkland, Jian Qian, Bradley Paul Sullivan
  • USE OF XENON AS NEUROPROTECTANT IN A NEONATAL SUBJECT
    Publication number: 20150216897
    Abstract: The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
    Type: Application
    Filed: February 10, 2015
    Publication date: August 6, 2015
    Inventors: Nicholas Peter Franks, Mervyn Maze
  • COMPOSITION FOR TREATING PSORIASIS
    Publication number: 20150216898
    Abstract: A dermal composition for treating or soothing psoriasis lesions, wherein the composition comprises a tar extract, a corticosteroid, an antipruritic, an antibiotic, urea, an absorption base, water, lanolin, and propylene glycol.
    Type: Application
    Filed: September 3, 2013
    Publication date: August 6, 2015
    Applicant: PSORIASIS+CREAMS SWENDEN AB
    Inventor: Ana Moll Lorca